Affiliations 

  • 1 Jose Enrique Montoya, MD. Transplant Institute, Section of Medical Oncology, Department of Internal Medicine, National Kidney and Transplant Institute, East Avenue, Quezon City, Philippines. jeymontoya@gmail.com
  • 2 H G Luna, MD. Section of Medical Oncology, Department of Internal Medicine, National Kidney and Transplant Institute (NKTI), Quezon City, Philippines.
  • 3 A B Morelos, MD. Section of Medical Oncology, Department of Internal Medicine, National Kidney and Transplant Institute (NKTI), Quezon City, Philippines.
  • 4 M M Catedral, MD. Section of Medical Oncology, Department of Internal Medicine, National Kidney and Transplant Institute (NKTI), Quezon City, Philippines.
  • 5 A L Lava, MD. Section of Medical Oncology, Department of Internal Medicine, National Kidney and Transplant Institute (NKTI), Quezon City, Philippines.
  • 6 J R Amparom, MD. Section of Medical Oncology, Department of Internal Medicine, National Kidney and Transplant Institute (NKTI), Quezon City, Philippines.
  • 7 G R Cristal-Luna, MD. Section of Medical Oncology, Department of Internal Medicine, National Kidney and Transplant Institute (NKTI), Quezon City, Philippines.
Med J Malaysia, 2013 Apr;68(2):153-6.
PMID: 23629563

Abstract

Fluorouracil, doxorubicin, cyclophosphamide protocol (FAC) is a commonly used regimen for breast cancer due to its proven efficacy, acceptable toxicity, high affordability. While hepatic insufficiency dosing for doxorubicin and fluorouracil have been set, there is paucity of data in the literature on how to reduce doses in renal insufficiency. We sought to determine whether there is an association with pre-chemotherapy creatinine clearance, and the occurrence of clinically significant grade 3 to 5 neutropenia during the course of FAC chemotherapy.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications